A Cleveland Clinic psychiatrist discusses what the latest research suggests causes bipolar, what the individual experiences, ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Many medications that are commonly referred to as "weight loss drugs" are not actually FDA-approved for this purpose. One of ...

With increasing concern over mental health in last few years, the medicines like Caplyta (lumateperone) from Intra-Cellular ...

Johnson & Johnson announced Monday its agreement to acquire biopharmaceutical company Intra-Cellular Therapies Inc. for ...

Johnson & Johnson and Intra-Cellular Therapies, Inc. have announced that they have entered into a definitive agreement under ...

Compulsive spending can be a symptom in the manic phase of bipolar disorder. Read more to find out what triggers this ...

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

New Brunswick-based Johnson & Johnson and Bedminster-based Intra-Cellular Therapies, Inc. have entered into a definitive agreement ...

After five novels about neurological conditions, the Still Alice author pens an empathetic portrayal of life with mental ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...